BioXcel Therapeutics (BTAI) Q3 2024 earnings summary

Executive summary

• Two pivotal Phase III trials for BXCL501 are underway: SERENITY At-Home for bipolar/schizophrenia agitation and TRANQUILITY In-Care for Alzheimer's-related agitation, with the first patient randomized in SERENITY At-Home.

• SERENITY At-Home trial began enrollment in September 2024, projected to last 9–12 months.

• BXCL501 is also being studied for chronic treatment, including a DoD-funded phase II study for acute stress disorder at UNC Chapel Hill.

• The company completed multiple workforce reductions in 2023 and 2024, shifting focus to core neuroscience programs and cost containment.

• IGALMI patent portfolio strengthened with 12 listed patents, latest expiring in 2043.

Financial highlights

• Net revenue from IGALMI was $214,000 for Q3 2024, down from $341,000 in Q3 2023, but nine-month revenue rose 89% year-over-year to $1.9 million.

• Cost of goods sold for Q3 2024 was $1.2 million, up from $512,000 in Q3 2023, mainly due to higher non-cash charges for excess or obsolete inventory.

• R&D expenses dropped to $5.1 million in Q3 2024 from $19.6 million in Q3 2023, reflecting reprioritization and workforce reduction.

• SG&A expenses fell to $7.7 million in Q3 2024 from $24.3 million in Q3 2023.

• Net loss for Q3 2024 was $13.7 million, improved from $50.5 million in Q3 2023.

Outlook and guidance

• SERENITY At-Home trial is expected to complete enrollment and reach data readout within 9–12 months from September 2024.

• TRANQUILITY In-Care trial protocol has received FDA feedback and is preparing to launch.

• Management expects current cash to fund operations through the end of 2024, but additional capital is required to continue as a going concern.

• Ongoing cost reductions and reprioritization are expected to lower annualized operating expenses by approximately $80 million.

• The company is actively seeking equity, debt, and partnership funding, and may further reduce headcount or scale back programs if needed.